Skip to content
Screener

Amneal Pharmaceuticals, Inc. AMRX Affordable Medicines — Other

Similar metrics at other companies

Sarepta Therapeutics, Inc. logo
SRPTAll Other Segments — Other Research And Development Expense
$19.85M-37.7%
Shattuck Labs, Inc. logo
STTKOther Research And Development — Other research and development expense
$1.9M+46.2%
Inhibrx Biosciences, Inc. logo
INBXReportable Segment — Other research and development
$2.91M-7.8%
XTI Aerospace, Inc. logo
XTIAADS — Other Research And Development Expense
$1.15M
XTI Aerospace, Inc. logo
XTIAUAS — Other Research And Development Expense
$48K
Travere Therapeutics, Inc. logo
TVTXReportable Segment — Other research and development
$4.84M+9.2%

Other financials

Income statement

See full
Revenue$796.2M+9.9%
Gross profit$334.5M+16.9%
Operating income$129.8M+16.5%
Net income$57.7M+157%
EPS (diluted)$0.18+157%

Balance sheet

See full
Cash & equivalents$127.6M+78.4%
Total debt$2.6B+18.0%
Total equity$33.0M+129%
Total assets$3.8B+10.3%

Cash flow

See full
Operating cash flow-$21.2M-125%
CapEx$30.7M+34.5%
Free cash flow-$51.9M-185%

Valuation

See full
Market cap$5.77B+129%
Enterprise value$8.21B+77.4%
P/E36.7×-711×
P/S1.9×+1.0×

Profitability

See full
Gross margin39.3%+1.7pp
Operating margin14.6%+1.4pp
Net margin5%+4.9pp
FCF margin4.1%-5.8pp

Returns & leverage

See full
Return on equity-52.8%-12.7pp
Debt / equity77.8×
Current ratio2.2×+0.8×

Where this comes from

Reported directly by Amneal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherResearchAndDevelopmentExpense.

The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 5:19 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001723128-26-000031
Line itemThree Months Ended June 30, 2026 / Affordable MedicinesThree Months Ended June 30, 2026 / SpecialtyThree Months Ended June 30, 2025 / Affordable MedicinesThree Months Ended June 30, 2025 / Specialty
Employee compensation and benefits$12,016$1,326$14,693$1,279
Materials and supplies8,7961,0228,108450
Product development and studies (1)(89)2,6157562,371
In-licensing and upfront milestones3,5006,350
Facilities costs1,479301,793735
Regulatory fees1,3342,932
Other (2)5,9871,0017,2671,230
Total$33,023$5,994$41,899$6,065

Item 1. Financial Statements (Unaudited)

FAQ

What is Amneal Pharmaceuticals, Inc.'s affordable medicines — other?
Amneal Pharmaceuticals, Inc. (AMRX) reported affordable medicines — other of $5.99M in Q2 2026.
How has Amneal Pharmaceuticals, Inc.'s affordable medicines — other changed year-over-year?
Amneal Pharmaceuticals, Inc.'s affordable medicines — other decreased by 17.6% year-over-year, from $7.27M to $5.99M.
What is the long-term trend for Amneal Pharmaceuticals, Inc.'s affordable medicines — other?
Over 3 years (2022 to 2025), Amneal Pharmaceuticals, Inc.'s affordable medicines — other has grown at a -9.3% compound annual growth rate (CAGR), from $38.1M to $28.41M.
What does affordable medicines — other mean?
Aggregates miscellaneous operating expenses that are not captured in specific line items but are necessary for segment operations. This category helps in understanding the total operational overhead and identifying hidden cost drivers.

Ask your AI about Amneal Pharmaceuticals, Inc.'s affordable medicines — other.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude